- Home
- XNET vs CRVS Comparison
XNET vs CRVS Comparison
Compare XNET & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNET
- CRVS
- Stock Information
- Founded
- XNET 2003
- CRVS 2014
- Country
- XNET China
- CRVS United States
- Employees
- XNET N/A
- CRVS N/A
- Industry
- XNET Computer Software: Prepackaged Software
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- XNET Technology
- CRVS Health Care
- Exchange
- XNET Nasdaq
- CRVS Nasdaq
- Market Cap
- XNET 402.6M
- CRVS 459.0M
- IPO Year
- XNET 2014
- CRVS 2016
- Fundamental
- Price
- XNET $6.96
- CRVS $8.79
- Analyst Decision
- XNET
- CRVS Strong Buy
- Analyst Count
- XNET 0
- CRVS 4
- Target Price
- XNET N/A
- CRVS $13.75
- AVG Volume (30 Days)
- XNET 369.3K
- CRVS 1.0M
- Earning Date
- XNET 11-13-2025
- CRVS 11-04-2025
- Dividend Yield
- XNET N/A
- CRVS N/A
- EPS Growth
- XNET 8740.73
- CRVS N/A
- EPS
- XNET 20.16
- CRVS N/A
- Revenue
- XNET $401,918,000.00
- CRVS N/A
- Revenue This Year
- XNET N/A
- CRVS N/A
- Revenue Next Year
- XNET N/A
- CRVS N/A
- P/E Ratio
- XNET $0.35
- CRVS N/A
- Revenue Growth
- XNET 27.19
- CRVS N/A
- 52 Week Low
- XNET $1.83
- CRVS $2.54
- 52 Week High
- XNET $11.03
- CRVS $9.55
- Technical
- Relative Strength Index (RSI)
- XNET 36.15
- CRVS 63.66
- Support Level
- XNET $6.40
- CRVS $8.34
- Resistance Level
- XNET $7.30
- CRVS $9.22
- Average True Range (ATR)
- XNET 0.47
- CRVS 0.55
- MACD
- XNET -0.09
- CRVS 0.01
- Stochastic Oscillator
- XNET 22.50
- CRVS 83.41
About XNET Xunlei Limited
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).